Patient characteristics
GH therapy . | Yes . | No . | P . |
|---|---|---|---|
| No. patients | 42 | 48 | — |
| Age at HCT, y, median (range) | 7.9 (1.0-14) | 11 (2.9-15) | .001* |
| Sex (female/male) | 13:29 | 22:26 | — |
| Cranial irradiation (%) | |||
| Yes | 21 (50) | 11 (23) | .007† |
| No | 21 | 37 | |
| Diagnosis at HCT, (%) | |||
| ALL | 28 (67) | 17 (35) | .001† |
| NHL | 2 (5) | 1 (2) | — |
| AML | 8 (19) | 15 (31) | — |
| MDS | 1 | 3 | — |
| CML | 3 (7) | 12 (25) | — |
| TBI regimen, (%) | |||
| 1200 cGy | 5 (12) | 12 (25) | — |
| 1400-1575 cGy | 37 (88) | 36 (75) | — |
| Type of HCT, (%) | |||
| Allogeneic identical sibling | 22 (52) | 19 (40) | — |
| Allogeneic unrelated donor | 6 (14) | 11 (23) | — |
| Allogeneic mismatched family | 12 (29) | 17 (35) | — |
| Autologous | 2 (5) | 1 (2) | — |
| GVHD, (%) | |||
| Acute | |||
| Grades 0-1 | 15 | 20 | — |
| Grades 2-4 | 27 (64) | 28 (58) | — |
| Chronic, extensive | 19 (45) | 21 (44) | — |
| Extensive steroid use, (%) | |||
| No | 39 (93) | 44 (92) | — |
| Yes | 3 (7) | 4 (8) | — |
| Follow-up, y, median (range) | 11.0 (3.2-23) | 11.2 (2.7-20.3) | — |
| Height SD at HCT, median (range) | –0.6 (–3.3-1.0) | 0 (–2.6-3.1) | .005* |
GH therapy . | Yes . | No . | P . |
|---|---|---|---|
| No. patients | 42 | 48 | — |
| Age at HCT, y, median (range) | 7.9 (1.0-14) | 11 (2.9-15) | .001* |
| Sex (female/male) | 13:29 | 22:26 | — |
| Cranial irradiation (%) | |||
| Yes | 21 (50) | 11 (23) | .007† |
| No | 21 | 37 | |
| Diagnosis at HCT, (%) | |||
| ALL | 28 (67) | 17 (35) | .001† |
| NHL | 2 (5) | 1 (2) | — |
| AML | 8 (19) | 15 (31) | — |
| MDS | 1 | 3 | — |
| CML | 3 (7) | 12 (25) | — |
| TBI regimen, (%) | |||
| 1200 cGy | 5 (12) | 12 (25) | — |
| 1400-1575 cGy | 37 (88) | 36 (75) | — |
| Type of HCT, (%) | |||
| Allogeneic identical sibling | 22 (52) | 19 (40) | — |
| Allogeneic unrelated donor | 6 (14) | 11 (23) | — |
| Allogeneic mismatched family | 12 (29) | 17 (35) | — |
| Autologous | 2 (5) | 1 (2) | — |
| GVHD, (%) | |||
| Acute | |||
| Grades 0-1 | 15 | 20 | — |
| Grades 2-4 | 27 (64) | 28 (58) | — |
| Chronic, extensive | 19 (45) | 21 (44) | — |
| Extensive steroid use, (%) | |||
| No | 39 (93) | 44 (92) | — |
| Yes | 3 (7) | 4 (8) | — |
| Follow-up, y, median (range) | 11.0 (3.2-23) | 11.2 (2.7-20.3) | — |
| Height SD at HCT, median (range) | –0.6 (–3.3-1.0) | 0 (–2.6-3.1) | .005* |